The Technical Analyst
IntelGenx Technologies [IGXT]
Exchange: PNK Industry: Biotechnology
IntelGenx Technologies Price, Forecast, Insider, Ratings, Fundamentals & Signals
-9.30% $0.162
America/New_York / 3 mai 2024 @ 15:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 28.28 mill |
| EPS: | -0.0600 |
| P/E: | -2.70 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 174.66 mill |
| Avg Daily Volume: | 0.0986 mill |
| RATING 2024-05-03 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.70 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -2.70 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.146 - 0.178 ( +/- 9.88%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-19 | Atai Life Sciences N.v. | Buy | 0 | Convertible Notes |
| 2023-11-28 | Atai Life Sciences N.v. | Buy | 4 053 750 | Warrant (Right to Buy) |
| 2024-03-08 | Atai Life Sciences N.v. | Buy | 1 000 000 | Convertible Notes |
| 2023-10-06 | Atai Life Sciences N.v. | Buy | 8 500 000 | Convertible Notes |
| 2024-03-08 | Atai Life Sciences N.v. | Buy | 4 000 000 | Warrant (Right to Buy) |
| INSIDER POWER |
|---|
| 99.01 |
| Last 94 transactions |
| Buy: 34 712 521 | Sell: 605 000 |
Forecast:
16:00 - $0.162
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.162
Forecast 2: 16:00 - $0.162
Forecast 3: 16:00 - $0.162
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.162 (-9.30% ) |
| Volume | 0.137 mill |
| Avg. Vol. | 0.0986 mill |
| % of Avg. Vol | 138.86 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IGXT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
IGXT
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
Latest Press Releases
2024-04-08 07:45:00 - Press Release
Intelgenx Announces First Parkinson's Disease Patients Dosed With Montelukast Versafilm® In Phase 2 ‘montpark' Clinical Trial
Saint laurent, quebec, april 08, 2024 (globe newswire) -- intelgenx corp. (tsx:igx) (otcqb:igxt) (the "company" or "intelgenx") today announced that montelukast versafilm® has been administered to the first parkinson's disease (“pd”) patients in the phase 2 (‘montpark') clinical trial.
2024-04-05 07:45:00 - Press Release
Intelgenx Updates Status Of Buprenorphine Buccal Film Anda
Saint laurent, quebec, april 05, 2024 (globe newswire) -- intelgenx corp. (tsx:igx) (otcqb:igxt) (the “company” or “intelgenx”) today announced that its co-developer, chemo research sl, through its agent and affiliate, xiromed llc (“xiromed”), has received a complete response letter (“crl”) from the u.s. food and drug administration (“fda”) regarding its resubmitted abbreviated new drug application (“anda”) for buprenorphine buccal film.
2024-03-21 07:30:00 - Press Release
Intelgenx Reports Fourth Quarter And Full-year 2023 Financial Results
Saint laurent, quebec, march 21, 2024 (globe newswire) -- intelgenx technologies corp. (tsx:igx)(otcqb:igxt) (the "company" or "intelgenx") today reported financial results for the three- and twelve-month periods ended december 31, 2023. all dollar amounts are expressed in u.s. currency, unless otherwise indicated, and results are reported in accordance with united states generally accepted accounting principles except where noted otherwise.
2024-03-14 16:30:00 - Press Release
Intelgenx To Report Fourth Quarter And Full Year 2023 Financial Results On March 21, 2024 – Conference Call To Follow
Saint laurent, quebec, march 14, 2024 (globe newswire) -- intelgenx technologies corp. (tsx:igx) (otcqb:igxt) (“intelgenx”), a leader in pharmaceutical films, today announced that it will release its fourth quarter and full year 2023 financial results before market open on thursday, march 21, 2024.
2024-03-11 07:45:00 - Press Release
Intelgenx Enters Into A Third Amended And Restated Loan Agreement With Atai Life Sciences
Saint laurent, quebec, march 11, 2024 (globe newswire) -- intelgenx technologies corp. (tsx:igx) (otcqb:igxt) (the “company”) announces that its wholly-owned subsidiary, intelgenx corp. (“intelgenx corp.”), has entered into a third amended and restated loan agreement dated as of march 8, 2024 (amending the second amended and restated loan agreement dated as of september 30, 2023) (the “loan agreement”) with atai life sciences ag (“atai”), pursuant to which, among other things, atai has agreed to make (i) one (1) additional term loan in the amount of us$1,000,000 to intelgenx corp., which loan is to be disbursed within three (3) business days of the execution of the loan agreement (the “first tranche loan”), and (ii) one (1) additional term loan in the amount of us$1,000,000 to intelgenx corp...
Latest News
2024-03-14 16:30:00 - GlobeNewsWire
IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow
SAINT LAURENT, Quebec, March 14, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its fourth quarter and full year 2023 financial results before market open on Thursday, March 21, 2024.
2023-11-09 20:26:09 - Seeking Alpha
IntelGenx Technologies Corp. (IGXT) Q3 2023 Earnings Call Transcript
IntelGenx Technologies Corp. (OTCQB:IGXT) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Stephen Kilmer – Investor Relations Dwight Gorham – Chief Executive Officer Andre Godin – President and Chief Financial Officer Tommy Kenny – Senior Vice President and General Counsel Conference Call Participants Hugh Kelly – Private Investor David Nguyen – Private Investor Operator Greetings. Welcome to IntelGenx's Third Quarter 2023 Financial Results Conference Call.
2023-11-02 16:45:00 - GlobeNewsWire
IntelGenx to Report Third Quarter 2023 Financial Results on November 9, 2023 – Conference Call to Follow
SAINT LAURENT, Quebec, Nov. 02, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its third quarter 2023 financial results after market close on Thursday, November 9, 2023.
2023-08-14 23:47:09 - Seeking Alpha
IntelGenx Technologies Corp. (IGXT) Q2 2023 Earnings Call Transcript
IntelGenx Technologies Corp. (OTCQB:IGXT) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Stephen Kilmer - Investor Relations Dwight Gorham - Chief Executive Officer Andre Godin - President and CFO Dr. David Kideckel - Senior Vice President and Head, Corporate Development and Strategic Alliances Dr. Frank Pietrantonio - Director, Clinical Research Tommy Kenny - Senior Vice President and General Counsel Dr. Horst Zerbe - Chairman Conference Call Participants Steve Gee - Wedbush Operator Greetings. And welcome to the IntelGenx Second Quarter 2023 Financial Results Conference Call.
2023-08-07 16:30:00 - GlobeNewsWire
IntelGenx to Report Second Quarter 2023 Financial Results on August 14, 2023 – Conference Call to Follow
SAINT LAURENT, Quebec, Aug. 07, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its second quarter 2023 financial results after market close on Monday, August 14, 2023.
2023-07-06 16:30:00 - GlobeNewsWire
IntelGenx Announces Voting Results on Election of Directors
SAINT LAURENT, Quebec, July 06, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces that, at the annual meeting of shareholders of the Company held on May 9, 2023 (the “Annual Meeting”), shareholders voted in favour of all items of business put forth by the Company, including the election of the directors, by a majority of the votes cast by shareholders present or represented by proxy.
2023-05-11 22:58:06 - Seeking Alpha
IntelGenx Technologies Corp. (IGXT) Q1 2023 Earnings Call Transcript
IntelGenx Technologies Corp. (OTCQB:IGXT) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Stephen Kilmer - Investor Relations Horst Zerbe - Chief Executive Officer Andre Godin - President and Chief Financial Officer David Kideckel - Head-Corporate Development and Strategic Alliances Frank Pietrantonio - Director-Clinical Research Tommy Kenny - Vice President-Legal Affairs and Intellectual Property and General Counsel Dwight Gorham - Newly Appointed President and CEO Operator Greetings and welcome to the IntelGenx First Quarter 2023 Financial Results Conference Call. At this time all participants are in listen-only mode.
2023-05-04 16:30:00 - GlobeNewsWire
IntelGenx to Report First Quarter 2023 Financial Results on May 11, 2023 – Conference Call to Follow
SAINT LAURENT, Quebec, May 04, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its first quarter 2023 financial results after market close on Thursday, May 11, 2023.
2023-03-29 21:57:04 - Seeking Alpha
IntelGenx Technologies Corp. (IGXT) Q4 2022 Earnings Call Transcript
IntelGenx Technologies Corp. (OTCQB:IGXT) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Stephen Kilmer – Investor Relations Horst Zerbe – Chief Executive Officer Andre Godin – President and Chief Financial Officer Frank Pietrantonio – Director-Clinical Research Tommy Kenny – Vice President-Legal Affairs and Intellectual Property and General Counsel David Kideckel – Head-Corporate Development and Strategic Alliances Conference Call Participants Hugh Kelly – Private Investor Trevor Lee – Private Investor Lindsey Murphy – Private Investor Operator Greetings and welcome to the IntelGenx Fourth Quarter and Full Year 2022 Financial Results Conference Call...
2023-03-24 16:15:00 - GlobeNewsWire
IntelGenx Revises Fourth Quarter and Full Year 2022 Financial Results Reporting and Conference Call Date to March 29, 2023
SAINT LAURENT, Quebec, March 24, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that, further to its press release of March 23, 2023, it now plans to release its fourth quarter and full year 2022 financial results after market close on Wednesday, March 29, 2023.